The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Interim safety analysis from a randomized, open-label, multicenter, phase III trial of capecitabine plus oxaliplatin (XELOX) versus capecitabine (X) as first-line chemotherapy in elderly patients with advanced gastric cancer (AGC).
In Gyu Hwang
No relevant relationships to disclose
Jung Hun Kang
No relevant relationships to disclose
Soonil Lee
No relevant relationships to disclose
Hyo Rak Lee
No relevant relationships to disclose
Hui Young Lee
No relevant relationships to disclose
Jun Ho Ji
No relevant relationships to disclose
Jeeyun Lee
No relevant relationships to disclose
Se Hoon Park
No relevant relationships to disclose
Joon Oh Park
No relevant relationships to disclose
Young Suk Park
No relevant relationships to disclose
Ho Yeong Lim
No relevant relationships to disclose
Won Ki Kang
No relevant relationships to disclose